Genetic testing cut adverse events in heart patients

By Melissa Busch, LabPulse.com assistant editor

August 27, 2020 -- Personalized genetic testing led to a 34% decrease in the number of patients who had serious adverse events following balloon angioplasties, according to results published August 25 in the Journal of the American Medical Association.

Patients often will be prescribed the blood thinner clopidogrel to prevent blood clots after undergoing percutaneous coronary intervention procedures, which can irritate blood vessels and cause clots.

However, the gene CYP2C19, which is required to activate clopidogrel, does not work in about 30% of patients. For that reason, individuals with this genetic variant are at a greater risk of experiencing adverse events, like heart attacks or strokes, in the year following their procedures, according to the authors.

Current guidelines do not recommend genetic testing before prescribing clopidogrel. Therefore, the trial -- titled the Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI) trial -- aimed to determine whether genetic testing would decrease cardiovascular complications after the procedures.

In addition to the 34% drop in serious adverse events in patients, the researchers found a nearly 80% reduction in the rate of cardiovascular complications in the first three months of treatment among patients who received genetically guided therapy, according to the trial.

About 5,300 patients who were treated for heart artery blockage with one or more stents were enrolled in the TAILOR-PCI trial and monitored for one year. Half of the group was tested for the CYP2C19 gene variation, and the 35% who were carriers were treated with the alternative antiplatelet medication ticagrelor. The rest of the participants received clopidogrel.

The Mayo Clinic, Mayo Clinic Center for Individualized Medicine, and the National Heart, Lung, and Blood Institute funded the study. Spartan Bioscience supplied the genetic tests.

Healthy Nevada Project: Community genetic testing needed
Community-based genetic screening could identify people at increased risk for three common inherited genetic conditions, according to a study published...
Heart association offers advice on who should get genetic testing
The American Heart Association has released a new scientific statement on genetic testing and counseling for inherited cardiovascular diseases, including...
Procalcitonin test signals infection in heart attack patients
Elevated procalcitonin in blood appears to be a good biomarker for infections in patients who have had a myocardial infarction, with potential to ensure...
Older women benefit from genetic breast cancer testing
Postmenopausal women newly diagnosed with breast cancer -- but without any hereditary risk factors -- may benefit from genetic testing for cancer-related...
CVS Health paves way for genetic testing of cancer patients
CVS Health is launching a program that will facilitate genetic testing for cancer patients at the point of prescribing to guide personalized treatment...

Copyright © 2020 LabPulse.com

Last Updated ls 8/26/2020 12:45:23 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email